Janssen Research & Development, Johnson & Johnson
BIOGRAPHY
Speaker
Abstract
Over the last two decades, more than one hundred mAbs have been approved or are in regulatory review in the US and EU. This growth has led to an increasing need for developing rapid technologies to support the characterization of mAbs to secure drug product safety, quality, and efficacy. In this presentation we present several mass spectrometry-based technologies used in a stage appropriate manner to dramatically shorten timelines and improve throughput in biologics research. Examples include; automated and rapid sample preparation, multiplexed workflows, high-resolution SLIM-IMS-MS, RapidFire-MS, and our labs ongoing efforts for an end-to-end automated process from sample preparation to reporting.
For Research Use Only. Not for use in diagnostic procedures.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
MAY 29, 2024 | 9:00 AM
C.E. CREDITS
Histology laboratorians in the research world move fast, but those who perform cryosectioning know that these particular tissues require lighting speed and precision. Cryosectioning is the a...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
MAY 29, 2024 | 8:00 AM
A-TEEM spectroscopy is an emerging technique with huge potential for QC laboratories in the pharmaceutical and biopharmaceutical industries. We present a set of tools for A-TEEM spectroscopy...
JUN 19, 2024 | 8:30 AM
Join us for an illuminating webinar as we delve into the realm of open automation with Inpeco, the global leader in Total Laboratory Automation. Discover how their groundbreaking s...
Loading Comments...